192 Response to 5-azacytidine in therapy-related malignant neoplasms (t-MN)

Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

“…At the 2010 ASH annual meeting, an overall response rate of 38% was reported for 60 tMDS/AML patients treated on the 5-aza compassionate use program in France [15]. The response rates in these reports and in the current study are roughly comparable to other DNMTI studies, albeit in the lower range of what has been reported, perhaps due to the high proportion of poor risk cytogenetics (63-75%) in our study and in the 3 other cited reports [13][14][15]. The overall response rates in the larger 5-aza studies are similar to our data, which were weighted more heavily toward the use of DAC, possibly supporting our prestudy decision to analyze the 5-aza and DAC recipients as a combined cohort.…”

“…At the May 2011 Edinburgh MDS meeting, 2 groups described response rates to 5-aza in tMDS patients. One group reported an ORR (CR, PR, mCR, HI) of 43% in 76 tMDS/AML patients and a survival advantage for patients who achieved SD or better response [13], while the other group reported an ORR of 26% in 19 tMDS patients [14]. At the 2010 ASH annual meeting, an overall response rate of 38% was reported for 60 tMDS/AML patients treated on the 5-aza compassionate use program in France [15].…”